Home
Off-the-shelf
Cell lines
EL4-hCD19-LZ
Cell lines

Humanized EL4-hCD19-LZ reporter tumor cell line

Contact Us

Design of the EL4-hCD19-LZ cell line

The EL-4 cell line was established from a C57BL/6 murine lymphoma. These cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

We generated an EL4-hCD19-LZ clonal cell line expressing high levels of human CD19 (NCBI GeneID: 930), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). EL4-hCD19-LZ cells form tumors in vivo when injected subcutaneously. Luciferase-ZsGreen (LZ) control cells are available.

‍

EL4-hCD19-LZ features

  • Express a fully human CD19
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Form tumors upon subcutaneous injection in fully immunocompetent mice

Clients

No items found.

Related resources and publications

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

pain research

nutrition

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

retinitis pigmentosa (RP)

retinal dystrophy disorder

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
PosterS
(
0
)
Scientific Articles
(
0
)
CommentarIes
(
0
)
Case studies
(
0
)
No results
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

Front Immunol

Dec 2023
Highlighted article
read the comment
CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

PLoS One

Jan 2023
Highlighted article
read the comment
ERα-36 regulates progesterone receptor activity in breast cancer

Breast Cancer Res

Jan 2020
T cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumor burden in multiple murine syngeneic models of solid cancer

Immunology

Jan 2020
SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2.

Nat Immunol

Jan 2019
Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Cancer Immunol Res

Jan 2019
Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

10 min read
-
Mar 2024
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read
-
Jun 2023
A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read
-
Jul 2022
Improving in vitro models: the coming of age of organoids

Organoids

6 min read
-
Mar 2018
iPS technology: Four factors that will change the world… some day

iPS technology

5 min read
-
Nov 2017
No results
No results

Validation data

Discover related products to

EL4-hCD19-LZ

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Immune checkpoint
PD-L1
CT26

CT26-Pd-l1-ko

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

CT26
Immune checkpoint
CD39

CT26-hCD39-LZ

The CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.

CT26
Immune checkpoint
EpCAM

CT26-hEpCAM-LZ

CT26-hEpCAM-LZ  clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.

CD20
Immune checkpoint
EL4

EL4-hCD20-LZ

The  EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.

CD39
MC38
Immune checkpoint

MC38-hCD39-LZ

The  MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form  infiltrated tumors in immunocompetent mice.

PD-L1
Immune checkpoint
MC38
PD-1

MC38-hPD-L1-LZ

The MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

MC38
Immune checkpoint
PD-L1
CD47

MC38-hPD-L1-hCD47-LZ

The MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.

MC38
Immune checkpoint
PD-L1
HER2

MC38-hPD-L1-hHER2-LZ

The  MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.

Humanized EL4-hCD19-LZ reporter tumor cell line

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.